Artivion to Participate in Upcoming Investor Conferences
11/08/2022 - 04:25 PM
ATLANTA Nov. 8, 2022 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.
Artivion's management team will present at the upcoming Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at the Lotte New York Palace. The Company's presentation is scheduled to begin at 9:10a.m. ET . A live webcast can be accessed through Artivion's website, www.artivion.com , on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
Members of the management team will also host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 17, 2022 . Due to the format of this event no webcast will be available.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia , Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com .
Contacts:
Artivion
D. Ashley Lee
Executive Vice President &
Chief Financial Officer
Phone: 770-419-3355
Gilmartin Group LLC
Brian Johnston / Lynn Lewis
Phone: 332-895-3222
investors@artivion.com
https://www.prnewswire.com/news-releases/artivion-to-participate-in-upcoming-investor-conferences-301672095.html
SOURCE Artivion, Inc.
AORT Rankings
#1241 Ranked by Stock Gains
AORT Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Country
US
City
Kennesaw
About AORT
cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife’s bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife’s cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife’s biofoam® surgica
